SCHEMBL676612

SCHEMBL676612

FC(F)(F)c1cc2ccccc2o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
HPGD P15428 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 1/20 0.45
CYP2A6 P11509 2/20 0.44
FLT3 P36888 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.44
MGLL Q99685 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
TYR P14679 1/20 0.42
DAO P14920 1/20 0.42
AKR1B1 P15121 1/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiazolidine SCHEMBL3313313 0.80 BCHE (0.38) KDM4EHPGDALDH1A1MAPTFLT3
SCHEMBL24045384 0.79 KDM4E (0.42) KDM4EHPGDCYP2A6FLT3LOXL2
SCHEMBL28750544 0.78 MAPT (0.45) KDM4EHPGDALDH1A1MAPTCYP2A6
SCHEMBL800706 0.78 KDM4E (0.44) KDM4EHPGDALDH1A1CYP2A6FLT3
SCHEMBL16595609 0.77 FLT3 (0.49) KDM4EHPGDALDH1A1FLT3RAB9A
SCHEMBL28190799 0.75 CA12 (0.47) KDM4EHPGDALDH1A1MAPTCYP2A6
SCHEMBL8036000 0.75 KDM4E (0.46) KDM4EHPGDALDH1A1MAPTCYP2A6
SCHEMBL23692162 0.75 MAOB (0.43) KDM4EHPGDALDH1A1CYP2A6FLT3
SCHEMBL5776749 0.75 FLT3 (0.46) KDM4EHPGDALDH1A1MAPTCYP2A6
SCHEMBL28190093 0.75 APP (0.39) KDM4EHPGDALDH1A1MAPTCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117417316-A Trifluoromethyl benzofuran derivative and preparation method thereof 陕西科技大学 2024-01-19 CN claimed
CN-110590722-B Synthesis method of 2-trifluoromethyl benzofuran derivative 温州大学 2022-11-04 CN claimed
CN-112210132-B Oil-resistant corrosion-resistant heel mark material and preparation method thereof 浙江中瑞橡胶高分子材料股份有限公司 2022-04-01 CN claimed
CN-113122061-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 CN claimed
CN-112210132-A Oil-resistant corrosion-resistant heel mark material and preparation method thereof 浙江中瑞橡胶高分子材料股份有限公司 2021-01-12 CN claimed
CN-110590722-A Synthesis method of 2-trifluoromethyl benzofuran derivative 温州大学 2019-12-20 CN claimed
US-4939140-A ALDOSE REDUCTASE INHIBITORS PFIZER INC. (US) 1990-07-03 US claimed
CN-117417316-B Trifluoromethyl benzofuran derivative and preparation method thereof 陕西科技大学 2026-03-27 CN disclosed
CN-117417316-B Trifluoromethyl benzofuran derivative and preparation method thereof 陕西科技大学 2026-03-27 CN disclosed
CN-116874452-B Synthesis method for synthesizing 3-methylbenzofuran structural compound by taking calcium carbide as alkynyl source 宁夏大学 2025-04-01 CN disclosed
CN-117460288-A Organic electroluminescent device, display panel and display device 京东方科技集团股份有限公司 2024-01-26 CN disclosed
CN-117417316-A Trifluoromethyl benzofuran derivative and preparation method thereof 陕西科技大学 2024-01-19 CN disclosed
CN-117417316-A Trifluoromethyl benzofuran derivative and preparation method thereof 陕西科技大学 2024-01-19 CN disclosed
US-7192971-B2 4-Heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein BAYER AKTIENGESELLSCHAFT (DE) 2007-03-20 US disclosed
US-7192971-B2 4-Heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein BAYER AKTIENGESELLSCHAFT (DE) 2007-03-20 US disclosed
US-20070054839-A1 Method of inhibiting remnant lipoprotein production JAPAN TOBACCO INC. (JP) 2007-03-08 US disclosed
US-20070054839-A1 Method of inhibiting remnant lipoprotein production JAPAN TOBACCO INC. (JP) 2007-03-08 US disclosed
WO-2005117869-A1 COMBINATIONS COMPRISING (S)-AMLODIPINE AND A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, AND METHODS FOR REDUCING HYPERTENSION SEPRACOR INC. (US) 2005-12-15 WO disclosed
WO-2004004777-A1 USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS PFIZER PRODUCTS INC. (US) 2004-01-15 WO disclosed
WO-2004004778-A1 USE OF CETP INHIBITORS AND OPTIONALLY HMG COA REDUCTABLE INHIBITORS AND/OR ANTIHYPERTENSIVE AGENTS PFIZER PRODUCTS INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054839-A1 Method of inhibiting remnant lipoprotein production CETP, PCSK9, LIPA KDM4E 2545/4885HPGD 1620/4885ALDH1A1 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.